Osteoporosis News and Research

Latest Osteoporosis News and Research

U.S. Court rules in Merck's favor in Flemings case involving FOSAMAX

Merck said today that U.S. District Court Judge John F. Keenan granted summary judgment in Merck's favor in Flemings v. Merck. Flemings is the second of three cases involving FOSAMAX (alendronate sodium) designated by the federal MDL court as a bellwether trial case.

24 Nov 2009

Flaxseed oil may reduce reduce the risk of osteoporosis

Animal studies suggest that adding flaxseed oil to the diet could reduce the risk of osteoporosis in post-menopausal women and women with diabetes, according to a report to be published in the International Journal of Food Safety, Nutrition and Public Health.

23 Nov 2009

World Congress on Osteoporosis 2010: Researchers invited to contribute their abstracts

Researchers are invited to contribute their abstracts to the World Congress on Osteoporosis 2010 (IOF WCO - ECCEO10), the largest global meeting devoted to all aspects of osteoporosis and osteoarthritis research and patient care. The Congress will be held in Florence, Italy from May 5-8, 2010.

21 Nov 2009

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis.

20 Nov 2009

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

Ligand Pharmaceuticals Incorporated announced today that it has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that is due to expire at the end of December.

19 Nov 2009

VisEn Medical launches two new agents for imaging quantification

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense® 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn's OsteoSense 680 and 750 products, and is expected to further expand the utilization of this agent family in enabling in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis.

19 Nov 2009

Findings suggest athletes abuse non-approved therapeutic compounds for performance enhancing effects

Researchers from the German Sport University Cologne in Germany found that non-steroidal and tissue-selective anabolic agents such as Selective Androgen Receptor Modulators (SARMs) are being sold on the black market for their performance enhancing qualities.

19 Nov 2009

New mathematical model may hasten drug development for Parkinson's Disease

Australian scientists have significantly advanced our understanding of dopamine release from nerve cells, findings that should speed the development of more effective drugs for treating Parkinson's Disease.

19 Nov 2009

Third-quarter 2009 results announced by Tongjitang Chinese Medicines

Tongjitang Chinese Medicines Company, a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced its financial results for the quarter ended September 30, 2009 and the repurchase of ordinary shares in a private transaction.

18 Nov 2009

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta Incorporated today announced financial results for the quarter and nine months ended September 30, 2009. The Company also announced a restructuring, reduction in workforce, and re-ordering of clinical development priorities.

16 Nov 2009

Tips to ensure adequate vitamin D levels

Thousands of independent studies in the past three years have revealed a strong connection between vitamin D deficiency and increased risk for a variety of serious illnesses including as many as 22 forms of cancer, heart disease, diabetes, osteoporosis and multiple sclerosis, as well as common colds and flus.

16 Nov 2009

Spine Care Institute established by Hospital for Special Surgery

Hospital for Special Surgery today announced the establishment of one of the most comprehensive centers of excellence in the country for the treatment of all nonoperative and operative spine disorders.

16 Nov 2009

Effects of vitamin D deficiency amplified by lower levels of sex hormone estrogen

Researchers at Johns Hopkins are reporting what is believed to be the first conclusive evidence in men that the long-term ill effects of vitamin D deficiency are amplified by lower levels of the key sex hormone estrogen, but not testosterone.

16 Nov 2009

$Post-menopausal women in Asia hospitalized with fragility fracture are not aware whether they had osteoporosis or not$

Post-menopausal women in Asia hospitalized with fragility fracture are not aware whether they had osteoporosis or not

New results from a survey of 1,122 post-menopausal women in Asia found that nearly half (48.5 percent) were not aware whether or not they had osteoporosis despite being hospitalized with a fragility fracture.

13 Nov 2009

People in their 60s may have more disabilities than their counterparts from prior generations

In a development that could have significant ramifications for the nation's health care system, Baby Boomers may well be entering their 60s suffering far more disabilities than their counterparts did in previous generations, according to a new UCLA study. The findings, researchers say, may be due in part to changing American demographics.

13 Nov 2009

Galapagos third quarter 2009 financial results in line with management expectations

Galapagos NV announces today that third quarter 2009 operational and financial results were in line with management expectations. These results encourage the Company to retain full year guidance of EUR 100 million revenues, a growth of 30% compared to 2008. Galapagos' service division BioFocus will significantly increase its cash contribution to the Group result for the full year 2009.

13 Nov 2009

BioClinica to host a seminar on medical imaging for rheumatoid arthritis in clinical trials

BioClinica™, Inc., (NASDAQ: BIOC), a global provider of clinical trial services, today announced it will be hosting a seminar on November 18, 2009 highlighting new research, trends and updates from industry experts in rheumatoid arthritis. This event, which will be held in Lafayette, PA, is part of the continuing series of symposia hosted by the company for pharmaceutical and medical imaging executives over the past four years that addresses the challenges and approaches in conducting clinical trials.

From Clario 11 Nov 2009

Positive study data from Zosano Pharma's ZP-PTH transdermal patch for treating osteoporosis

Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, announced publication in the current issue of the Journal of Clinical Endocrinology and Metabolism of results from a positive phase 2 study of its rapid-delivery transdermal patch (ZP-PTH) for the treatment of postmenopausal osteoporosis.

9 Nov 2009

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Emisphere Technologies, Inc. today announced financial and operational results for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

Warner Chilcott reports a net income of $424.2M for the quarter ended September 30, 2009

Warner Chilcott plc today announced its results for the quarter ended September 30, 2009. Revenue in the quarter ended September 30, 2009 increased 9.0% to $252.8 million over the prior year quarter. The primary drivers of the increase in revenue in the quarter were the net sales of LOESTRIN 24 FE and ESTRACE Cream which were partially offset by net sales declines of other products, primarily TACLONEX.

9 Nov 2009

Osteoporosis News and Research

Latest Osteoporosis News and Research

U.S. Court rules in Merck's favor in Flemings case involving FOSAMAX

Flaxseed oil may reduce reduce the risk of osteoporosis

World Congress on Osteoporosis 2010: Researchers invited to contribute their abstracts

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

VisEn Medical launches two new agents for imaging quantification

Findings suggest athletes abuse non-approved therapeutic compounds for performance enhancing effects

New mathematical model may hasten drug development for Parkinson's Disease

Third-quarter 2009 results announced by Tongjitang Chinese Medicines

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Tips to ensure adequate vitamin D levels

Spine Care Institute established by Hospital for Special Surgery

Effects of vitamin D deficiency amplified by lower levels of sex hormone estrogen

Post-menopausal women in Asia hospitalized with fragility fracture are not aware whether they had osteoporosis or not

People in their 60s may have more disabilities than their counterparts from prior generations

Galapagos third quarter 2009 financial results in line with management expectations

BioClinica to host a seminar on medical imaging for rheumatoid arthritis in clinical trials

Positive study data from Zosano Pharma's ZP-PTH transdermal patch for treating osteoporosis

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Warner Chilcott reports a net income of $424.2M for the quarter ended September 30, 2009

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Osteoporosis News and Research

Latest Osteoporosis News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in